SCHEMBL4335075

SCHEMBL4335075

NC(=O)c1cc(Oc2ccc(NC(=S)NC(=O)Cc3ccc(F)cc3)cc2)ccn1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MET P08581 8/20 0.53
P2RX3 P56373 4/20 0.51
AXL P30530 1/20 0.50
PDGFRA P16234 3/20 0.49
KIT P10721 1/20 0.49
RAF1 P04049 1/20 0.48
KDR P35968 2/20 0.46
KMT2A Q03164 1/20 0.46
RAB9A P51151 1/20 0.46
CSF1R P07333 2/20 0.46
PDGFRB P09619 2/20 0.46
FLT3 P36888 2/20 0.46
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HIPK4 Q8NE63 2/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1137651 0.91 MET (0.63) METP2RX3PDGFRARAF1KDR
SCHEMBL4329988 0.90 MET (0.59) METPDGFRAKITRAF1KDR
SCHEMBL4335649 0.89 MET (0.66) METAXLPDGFRAKDRCSF1R
SCHEMBL4324306 0.89 MET (0.49) METP2RX3AXLPDGFRARAF1
SCHEMBL4335084 0.88 MET (0.67) METAXLPDGFRAKITKDR
SCHEMBL4323162 0.87 MET (0.55) METP2RX3AXLPDGFRAKIT
SCHEMBL1136788 0.85 SMN1; SMN2 (0.57) METAXLPDGFRAKITKMT2A
SCHEMBL4337508 0.82 MET (0.49) METAXLPDGFRAKITKDR
SCHEMBL4329494 0.82 MET (0.56) METP2RX3PDGFRAKITRAF1
SCHEMBL4322992 0.81 MET (0.66) METAXLPDGFRAKDRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1719762-B1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) EISAI R&D MAN CO LTD (JP) 2012-06-27 EP claimed
EP-1719762-B1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) EISAI R&D MAN CO LTD (JP) 2012-06-27 EP disclosed
US-7531532-B2 Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-05-12 US disclosed
US-20070270421-A1 Novel pyridine Derivative and Pyrimidine Derivative (1) EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-11-22 US disclosed
EP-1719763-A1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2) Eisai Co., Ltd. (JP) 2006-11-08 EP disclosed
EP-1719762-A1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) Eisai Co., Ltd. (JP) 2006-11-08 EP disclosed
US-20050277652-A1 Novel pyridine derivative and pyrimidine derivative EISAI CO., LTD. (JP) 2005-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270421-A1 Novel pyridine Derivative and Pyrimidine Derivative (1) HGF, MET, FLT1 MET 2/4885P2RX3 662/4885AXL 87/4885
US-20050277652-A1 Novel pyridine derivative and pyrimidine derivative HGF, MET, HDGF MET 2/4885P2RX3 692/4885AXL 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.